BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
PSEC
Prospect Capital Corporation
There isn't enough reported data to score PSEC yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
PSEC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| N/A | |
| N/A |
PSEC's profitability is currently stable, but its revenue is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like PSEC.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
PSEC PE Valuation
PSEC has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over PSEC on the outlook, with more favorable earnings and revenue expectations.
PSEC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PSEC's earnings and revenue to decline, with profitability weakening.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the stronger earnings trend. Trailing diluted EPS is up 14% for BAC versus PSEC down 505%.
PSEC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.32 | — |
| Q3 2025 | -$0.89 | -$0.67 |
| Q2 2025 | -$1.35 | -497% |
| Q1 2023 | -$0.51 | -124% |
| Q4 2022 | $0.14 | -94% |
| Q3 2022 | $0.62 | -76% |
| Q2 2022 | $1.41 | -44% |
| Q1 2022 | $2.14 | -7.8% |
| Q4 2021 | $2.39 | +103% |
PSEC lost $0.89 per share over the past year, a bigger loss than the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the stronger quarterly revenue trend. Revenue is up 6.7% for BAC versus down 104% for PSEC.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
PSEC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $203.3M | -32% |
| Q4 2021 | $293.9M | -17% |
| Q3 2021 | $253.7M | +19% |
| Q2 2021 | $284.3M | +37% |
| Q4 2020 | $353.2M | +753% |
PSEC's revenue has slid since its 2020 peak: −$11M last quarter, down 104% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | 81% | -1.9 points |
| Q4 2021 | 86% | -0.3 points |
| Q3 2021 | 84% | +4.6 points |
| Q2 2021 | 86% | +7.2 points |
| Q1 2021 | 83% | N/A |
| Q4 2020 | 87% | +114 points |
| Q3 2020 | 79% | N/A |
| Q2 2020 | 79% | N/A |
PSEC's operating margin was 81% last quarter, down 1.9 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
PSEC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $381.7M | +37% |
| Q2 2026 | -$43.9M | -$36.3M |
| Q1 2026 | $195.7M | +149% |
| Q4 2025 | $85.6M | -69% |
| Q3 2025 | $279M | +61% |
| Q2 2025 | -$7.6M | -106% |
| Q1 2025 | $78.6M | +$100.8M |
| Q4 2024 | $278.5M | +251% |
PSEC has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over PSEC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
PSEC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -44% | -405M shares |
| 1 year | +18% | +81M shares |
| 3 years | -4.2% | -22.9M shares |
| 5 years | +37% | +143M shares |
| Available history | +43% | +157M shares |
PSEC has 524M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
PSEC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 4.7x | High |
| Q1 2022 | 2.9x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q3 2021 | 2.0x | Moderate |
| Q2 2021 | 2.3x | Moderate |
| Q1 2021 | 2.3x | Moderate |
| Q4 2020 | 4.6x | High |
| Q3 2020 | 16.0x | High |
PSEC's net debt is about 4.7 years of its operating earnings (EBITDA), up from 2.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like PSEC.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
PSEC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 13.6 | Oversold |
PSEC's weekly RSI is 26 (oversold) and its Stochastic is 14 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
PSEC PE vs Financial Services Sector
| Metric | PSEC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
PSEC has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over PSEC on trend strength, trading above more of its moving averages.
PSEC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.68 | 16% below |
| 20 week MA | $2.01 | 30% below |
| 50 week MA | $2.36 | 40% below |
| 100 week MA | $2.91 | 52% below |
| 200 week MA | $4.40 | 68% below |
PSEC is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over PSEC on returns for 2026, with the stronger performance.
PSEC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.51 | $5.46 | -16% |
| 2021 | $5.46 | $8.43 | +54% |
| 2022 | $8.43 | $7.16 | -15% |
| 2023 | $7.16 | $5.99 | -16% |
| 2024 | $5.99 | $4.26 | -29% |
| 2025 | $4.26 | $2.51 | -41% |
| 2026 YTD | $2.51 | $1.41 | -44% |
PSEC has finished four years in a row lower, and it's down 44% so far in 2026.